Clinton’s Attacks on Drug Prices Leave Health Stocks Reeling
- Mylan drops after Democratic nominee urges EpiPen price cut
- Clinton’s statements have dropped pharmaceutical shares before
Mylan CEO Faces Calls to Explain 400% EpiPen Increase
This article is for subscribers only.
Drugmakers are learning to duck for cover when Hillary Clinton puts them in her sights.
The Democratic presidential nominee’s influence was on display again Wednesday, when she sent Mylan NV’s shares plummeting as much as much as 6.2 percent within minutes of calling for the company to drop prices of its EpiPen emergency allergy shot. It marked the third time over the past year that Clinton’s comments roiled drug stocks.